Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study

• Published in: Osteoporosis international Vol. 27; no. 1; pp. 351 - 359
• Main Authors: Ebina, K., Noguchi, T., Hirao, M., Hashimoto, J., Kaneshiro, S., Yukioka, M., Yoshikawa, H.
• Format: Journal Article
• Language: English
• Published: London Springer London 01.01.2016; Springer Nature B.V
• Subjects: Absorptiometry, Photon - methods; Adult; Aged; Aged, 80 and over; Alendronate - administration & dosage; Alendronate - therapeutic use; Arthritis, Rheumatoid - complications; Arthritis, Rheumatoid - physiopathology; Biomarkers - blood; Bone Density - drug effects; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - therapeutic use; Bone Remodeling - drug effects; Diphosphonates - administration & dosage; Diphosphonates - therapeutic use; Drug Administration Schedule; Drug Substitution; Drug therapy; Endocrinology; Female; Humans; Imidazoles - administration & dosage; Imidazoles - therapeutic use; Medicine; Medicine & Public Health; Middle Aged; Original Article; Orthopedics; Osteoporosis; Osteoporosis, Postmenopausal - drug therapy; Osteoporosis, Postmenopausal - etiology; Osteoporosis, Postmenopausal - physiopathology; Osteoporotic Fractures - etiology; Osteoporotic Fractures - physiopathology; Osteoporotic Fractures - prevention & control; Patient Preference; Prescription drugs; Prospective Studies; Rheumatoid arthritis; Rheumatology; Risedronate Sodium - administration & dosage; Risedronate Sodium - therapeutic use; Risk factors; Risedronate; Osteoporosis; Minodronate; Alendronate; Rheumatoid arthritis

Summary Switching weekly ALN or RIS to monthly MIN in patients with RA, of whom two-thirds were treated with low-dose PSL, significantly decreased bone turnover markers and increased BMD at 12 months, suggesting that monthly MIN may be an effective alternative treatment option of oral bisphosphonate...